BIOX vs LIN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health scores paint a dire picture: BIOX has a Piotroski F-Score of just 2/9, indicating severe financial weakness. Despite low valuation multiples like a Price/Book of 0.29 and Price/Sales of 0.24, the company is unprofitable with a -17.72% profit margin and deteriorating fundamentals, including -16.40% YoY revenue growth and a -300% YoY EPS decline. Earnings volatility is extreme, with a history of massive negative surprises averaging -268.89% over the last four quarters, and the stock has lost over 85% of its value in five years. While the Forward P/E of 1.88 may appear attractive, it is unsupported by cash flow, balance sheet clarity, or consistent earnings, and the lack of an Altman Z-Score due to missing data further elevates risk.
LIN shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
BIOX vs LIN: Head-to-Head Comparison
This page compares Bioceres Crop Solutions Corp. (BIOX) and Linde plc (LIN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.